Hey folks, it's Karen, Head of Data Science at Stock Card. This week I used the COVID-19 Testing Kit and meshed it with one fundamental indicator and two technical indicators using the new Filter function on the Discover page, used to result to come up with stock on my Watchlist. Let me share with you how I went about this screening.
Steps to follow
Visit Stock Card's Discover page, and follow these steps:
If you are a Stock Card user (on our free Starter plan or premium plans), you can see the final results by clicking on this link. It is noteworthy that the results may vary day to day due to price changes in the stocks included in the collection. As of the closing on Friday, September 11, 10 stocks are included in the screening results. Click to view the results, or continue reading.
Using filter results
The overall market has been quite volatile since the indices (e.g., Nasdaq-100, S&P 500) peaked on September 2. In particular, the rally of tech stocks fueled by Softbank has receded, and cautious investors may be inclined to refrain from “buying the dip” in the FAANG and tech stocks resulting in drastic declines in some of Stock Card most popular stocks. What other stocks can investors consider to diversify their portfolios away from the technology sector? Investing in the stocks in the COVID-19 Testing Kit collection could be an excellent way to get exposure to the biotech and healthcare sectors and diversify one’s portfolio.
Let’s take Thermo Fisher Scientific Inc (NYSE: TMO), one of the ten stocks in the filtering results, as an example.
Add to watchlist
The chart below shows that TMO has outperformed the S&P 500 index throughout the year and is very close to the Nasdaq-100 (NDX) Year-to-Date returns daily based on returns. In the most recent pullback since Sept 3, as both S&P 500 and Nasdaq have been laggard, TMO has shown increasing strength, which is reflected in the daily returns. This may qualify TMO as a good addition to your watchlist.
Investing in biotechnology companies that focus on the fight against COVID-19 involves understanding four main components: diagnostics, cure, vaccine, and distribution. More than 100 companies are competing in the vaccine development race, and several others are already getting ready to produce and distribute it. However, to contain the spread, diagnostic testing is an important frontier as the vaccine development is. As always, what becomes a society's priority tends to become a noteworthy investment too. This week, we turn our focus on COVID-19 Testing Kit stocks to give StockCardians and our broader community a starting point for their fight against COVID-19, investing-style.
The overall process of diagnostic testing depends on several different products such as swabs, glass vials, RT-PCR testing machines, a laboratory apparatus most commonly in DNA segmenting via the polymerase chain reaction (PCR), electronic or disposable pipettes, filter tips, and refrigerated microcentrifuges. To those products, one can add services such as test sample transportation and imaging centers. To build a robust list of companies involved in manufacturing testing kits and distribute diagnostic testing, we first referred to Stock Card’s proprietary market database to look for diagnostic testing companies. We then validated the list with holdings of exchange-traded funds such as the GERM ETF, which seeks to track the Prime Treatments, Testing, and Advancements Index.
Because of the priority and popularity of the COVID-19- related topics, almost every pharmaceutical, and healthcare company associate its operations with developing a testing kit, vaccine, or cure. However, the tricky part of the research was to screen for companies that are much more committed to finding the cure, assisting with diagnostics, and producing materials needed for various efforts in the COVID-19 ecosystem and are achieving early success. Our analyst team spent more than two weeks evaluating the list qualitatively, and the result has turned out to be a reliable yet robust list of companies worthy of your attention.
Risk and opportunity
As always, when you invest in companies without a proven track record of product and financial success, it involves risk. The risk is exacerbated when dealing with biotechnology companies in the COVID-19 ecosystem of vaccine and testing kits developments and has no other revenue sources. Your investment success would have two possible extreme outcomes. Either the company succeeds, and you win with it. Or, despite all the efforts and stock price volatility, the investment loses all its value. A binary result is the most typical risk you'd need to be ready to face, should you choose to invest in the COVID-19 testing kit stocks. The evidence of such binary outcome is visible in the rapid decline of the stock prices of testing kit frontrunners such as Quidel, Hologic, and Quest Diagnostics, since the launch of the low-cost testing kit by Abbot.
While that's a substantial risk, it may also mean an opportunity. It is worth evaluating some of the beaten-down testing kits stocks to find well-managed companies that are not purely reliant on a testing kit's success and can recover into more reasonable valuation in the future.
After the thorough research and curation of the list, we identified more than 80 companies involved in producing the COVID-19 testing kits and providing diagnostic testing services. You can access them directly by clicking on the below button. Alternatively, type in "COVID-19 testing kit" in the search bar, and you get the list.
Stock Card's Founder and CEO invited Dr. Alex Koh from the Family Investments YouTube channel to dig deep and research Fastly's stock. There is a surprise stock pick at the end of the video. It may or may not be Crowdstrike (CRWD)!
Disclaimer: Stock Card, Inc. and Family Investments YouTube channel have an ongoing marketing partnership, and Stock Card sponsors some of Family Investments' videos and content.
Investing in promising innovations that can potentially shape the future could be one of the best long-term investment strategies. One prominent example is the Electric Vehicles market. Electric vehicles date back to the 1830s when the first generation of eco-friendly cars came about. Later on, companies like Tesla brought the technology into the limelight and made it somewhat affordable for mass production. Since then, the wave of fuel-efficient and low-emission cars has spread to all types of vehicles, including heavy trucks and trains, and the technology has even spread to adjacent markets such as electric spacecraft!
To become a part of such an innovative market, one can invest in the growing electric vehicle companies for several years and benefit from the long-term price appreciation. How do you find such companies, especially those that are not yet well-known but are developing the critical components of this truly future-defining industry?
When we say "electric vehicles," one would almost immediately think of Tesla! However, even though Tesla is one of the leading companies in this market, some well-established automakers such as Volkswagen, BMW, and Nissan, have entered into this new market as competitors. And, the story doesn't stop there. Who builds the batteries, the software, and other components that enable this industry?
To answer that question, Stock Card team (Shama Patwardhan, Head of LiveOps and Raj Arora, Research Analyst Intern) dug deep into the industry and identified the companies that are enabling the “Electric Vehicles” to evolve and grow.
Our research methodology
Investing in the electric vehicles industry is not limited to just EV manufacturing companies. A large number of companies support the supply chain, which qualifies them as potential investment choices. Investors may find hidden gems among these lesser-known companies.
We began our research by mapping all of the different markets associated with the electric vehicles manufacturing process. We looked at the various components manufacturers, electric car charging businesses, lithium-ion technology-based battery manufacturing companies, lithium miners, and software development that powers electric self-driving cars. Here are a few markets associated with the “Electric Vehicles” collection:
As we wrapped up our research on electric vehicles, we discovered close to 100 companies that belong to the "Electric Vehicles" collection.
Before jumping in, let's remember that this market is still relatively new, and investing in rapidly evolving but new technologies come with inherent investment risks. For instance, manufacturing electric vehicles requires a significant investment in the infrastructure, which may get delayed or impact investors' short-term returns. Moreover, several companies on this list are still in the early stage and do not have a commercial product (e.g., Nikola Corp). Investors may need to stay invested and be patient with their investment through several possible volatile periods before the investment pans out.
Keep those risks in mind and explore our new "Electric Vehicles" collection to discover investment-worthy companies to add to your watch-lists and portfolios
Disclaimer: Stock Card team owns shares of Tesla.
The Coronavirus pandemic engulfed the whole world at the beginning of 2020, bringing all economies to a standstill. Offices and stores closed down to prevent the spread of the virus. Developing, producing, and distributing a cure and vaccine to immunize the world population became a race many pharmaceutical companies have embarked on. Consequently, media, investors, and traders have been speculating, discussing, and pouring money into those pharmaceutical companies. The hope for a vaccine has fueled unprecedented market volatility we have rarely seen in the recent market history. After all, there is a race going on, the race to COVID-19 vaccine.
The launch of "COVID-19 Vaccine Race" collection
In May 2020, the United States government introduced a framework for 'Operation Warp Speed,' a national program to accelerate the development, production, and distribution of COVID-19 vaccines. The program aims to have the vaccines ready by January 2021. More than 100 biotech companies began investing in the development of vaccines for the COVID-19 virus in the first quarter of 2020. According to the Federal Drug Administration, as of June 2020, there have been approvals to more than 25 companies to fast track the development and testing of their vaccines. And, another 141 companies are still in the development phase.
Our research methodology
As always, the Stock Card team took on researching the most viable investment opportunities that our users and community must add to their watchlist, if they plan to participate in the race to the vaccine. We investigated different activities that support the development, production, and distribution of a vaccine and added a list of companies involved in the process to our collections and themes. This list enables you to discover promising companies to invest in easily should you choose to participate in the race to the vaccine.
To create the "COVID-19 Vaccine Race" collection, a lot of research went into understanding the whole process involved in the end-to-end development of the vaccine, and the pre- and post-vaccine steps required in the process. We identified all the industries and markets which play crucial roles in making the vaccine a success. For example, one of the primary core markets is the vaccine components and raw materials. Our research found a high demand for vaccine adjuvants, which are essential in any vaccine. Few other markets that are discussed less frequently but are as important as the vaccine development are the companies involved in the vaccine production, including glass vials, cold chain logistics, and syringes, and needles. Therefore, the race to a vaccine isn't only about Vaccine development and encompasses an entire ecosystem of companies working together to take the global population to immunity destination.
Here's a list of the primary markets vital to the vaccine development and distribution:
In the race to the COVID-19 vaccine, the competition between companies is fierce as all companies strive to win. We put together a list of 60 companies, accelerating their development to win the race. Some of these companies may be very small but watchlist-worthy. Some are large and stable, with several products already in the market. Start your research by visiting Stock Card's COVID-19 Vaccine Race collection. You can always add additional filters to narrow down the list to your portfolio's most suitable stocks.